Men living with HIV (MLHIV) have a high burden of human papillomavirus (HPV)-related cancer. Understanding serological dynamics of HPV in men can guide decisions on introducing HPV vaccination and monitoring impact.
Sofia Bandomia and her team in Portuguese-speaking Mozambique had long found it challenging to enroll men living with HIV in care and treatment. What she found 5,000 miles, 11 countries and a language away in Cote d’Ivoire changed that.
To achieve epidemic control of HIV by 2030, countries aim to meet 90‐90‐90 targets to increase knowledge of HIV‐positive status, initiation of antiretroviral therapy (ART) and viral suppression by 2020. This study assessed the progress towards these targets from 2014 to 2016 in South Africa as expanded treatment policies were introduced using population‐representative surveys. It concludes that achieving the first 90 target will require targeted and improved testing models for men.
South Africa’s health data demonstrate that young men are less likely to test for HIV and less likely to start treatment when diagnosed as HIV-positive. Young men living with HIV often transmit the virus to younger female partners, contributing to an inter-generational cycle of transmission.
The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.